AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Food Science and Human Wellness Article
PDF (2.4 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Open Access

Anthocyanins from purple corn affect gut microbiota and metabolome in inflammatory bowel disease patients under infliximab infusion: the SiCURA pilot study

Mirco Vaccaa,1, Eduardo Maria Sommellab,1, Marina Lisoc, Giulio Vernab,d, Aurelia Scaranoe, Annamaria Silac, Margherita Curloc, Mauro Mastronardic, Katia Petronif, Chiara Tonellif, Bruno Di Jesog, Angelo Santinoe, Vincenzo Vestutob, Fabrizio Merciaib, Gianluigi Giannellic, Pietro Campigliab, Maria De Angelisa, Marcello Chieppah( ), Francesco Maria Calabresea( )
Department of Soil, Plant and Food Science, University of Bari Aldo Moro, Bari 70126, Italy
Department of Pharmacy, School of Pharmacy, University of Salerno, Fisciano 84084, Italy
Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis”, Castellana Grotte 70013, Italy
Department of Medicine, Digestive Health Research Institute, Case Western Reserve University School of Medicine, Cleveland 44106, USA
Unit of Lecce, Institute of Sciences of Food Production C.N.R., Lecce 73100, Italy
Department of Biosciences, University of Milan, Milan 20133, Italy
Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce 73100, Italy
Department of Biological and Environmental Sciences and Technologies (DISTEBA), University of Salento, Lecce 73100, Italy

Peer review under responsibility of Tsinghua University Press.

1 These authors equally contributed to the article.

Show Author Information

Highlights

• In clinical practice, although the IFX infusion was recognized to be a promising strategy useful in alleviating symptoms, this is not able to completely avoid the incidence of IBD relapsing.

• An innovative antioxidant enriched supplementation was tested in IBD patients during IFX infusion, and it led to clinical improvement as well as an effect on the serum metabolome and the intestinal microbiota.

• The proposed adjuvant therapy can be a promising tool aimed at reducing disease related inflammation status and improving patient physiology.

Abstract

Nowadays, inflammatory bowel disease (IBD)-patient therapies are mainly based on corticosteroid, thiopurine, and immunomodulator treatments. Patients with active disease, that do not respond to corticosteroid and/or thiopurine treatment, can switch to the usage of the chimeric monoclonal antibody infliximab (IFX). However, to date, no treatment appeared to be conclusive in lowering the incidence of IBD relapses. With the aim to increase the effectiveness of IFX treatment, we combined it with an adjuvant purple corn supplementation enriched in anthocyanins. IBD-patients were enrolled before they underwent to the IFX-infusion, and they were allocated in 2 different study arms. Patients in the intervention-arm followed a dietary supplementation with purple corn water-soluble extract, whereas control patients had a daily consumption of red fruit tea. 16S rDNA gene-sequencing and high-resolution mass-spectrometry metabo-lipidomics analyses were conducted on stool and sera samples, respectively. As a result, the experimental intervention mainly affected the serum metabolome of IBD-patients by decreasing the concentration of specific lipids. Focusing on IBD patient annotated taxa, a significant decrease in Lactobacillus and Bifidobacterium relative abundances was found. As far as it concerns the ulcerative colitis patient subset, the experimental intervention led to a decrease in Alistipes and Erysipelotrichaceae UCG-003 genus abundances and a concomitant Parabacteroides increase. On the contrary, after treatment, Crohn’s disease patients did not exhibit metataxonomics differences at the genus level. At the end of the treatment that led to a reshaped microbiota community, the gathered data paves the way for the usage of a specifically designed probiotic supplementation as a valuable strategy for IBD-patients under IFX infusion.

Keywords

Inflammatory bowel diseaseinfliximab infusionAntioxidantsNutrigenomicsAdjuvant therapy

Electronic Supplementary Material

Download File(s)
fshw-13-6-3536_ESM1.docx (15.6 KB)
fshw-13-6-3536_ESM2.pdf (263 KB)

References

[1]

G.P. Ramos, K.A. Papadakis, Mechanisms of disease: inflammatory bowel diseases, Mayo. Clin. Proc. 94 (2019) 155-165. https://doi.org/10.1016/j.mayocp.2018.09.013.
Crossref Google Scholar
[2]

M. Lee M, E.B. Chang, Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues, Gastroenterology 160 (2021) 524-537. https://doi.org/10.1053/j.gastro.2020.09.056.
Crossref Google Scholar
[3]

D. Alsoud, B. Verstockt, C. Fiocchi, et al., Breaking the therapeutic ceiling in drug development in ulcerative colitis, Lancet. Gastroenterol. Hepatol. 6 (2021) 589-595. https://doi.org/10.1016/S2468-1253(21)00065-0.
Crossref Google Scholar
[4]

H. Sales-Campos, P.J. Basso, V.B.F. Alves, et al., Classical and recent advances in the treatment of inflammatory bowel diseases, Braz. J. Med. Biol. Res. 48 (2015) 96-107. https://doi.org/10.1590/1414-431X20143774.
Crossref Google Scholar
[5]

A. Pisani, P. Rausch, C. Bang, et al., Dysbiosis in the gut microbiota in patients with inflammatory bowel disease during remission, Microbiol. Spectr. 10 (2022) e00616-22. https://doi.org/10.1128/spectrum.00616-22.
Crossref Google Scholar
[6]

J. Torres, J. Hu, A. Seki, et al., Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice, Gut 69 (2020) 42-51. https://doi.org/10.1136/gutjnl-2018-317855.
Crossref Google Scholar
[7]

S. De Santis, M. Liso, M. Vacca, et al., Dysbiosis triggers ACF development in genetically predisposed subjects, Cancers 13 (2021) 283. https://doi.org/10.3390/cancers13020283.
Crossref Google Scholar
[8]

F. Rizzello, E. Spisni, E. Giovanardi, et al., Implications of the westernized diet in the onset and progression of IBD, Nutrients 11 (2019) E1033. https://doi.org/10.3390/nu11051033.
Crossref Google Scholar
[9]

N. Green, T. Miller, D. Suskind, et al., A review of dietary therapy for IBD and a vision for the future, Nutrients 11 (2019) E947. https://doi.org/10.3390/nu11050947.
Crossref Google Scholar
[10]

A. Rezaie, R.D. Parker, M. Abdollahi, Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci. 52 (2007) 2015-2021. https://doi.org/10.1007/s10620-006-9622-2.
Crossref Google Scholar
[11]

M. Chieppa, G. Giannelli, Immune cells and microbiota response to iron starvation, Front. Med. 5 (2018) 5109. https://doi.org/10.3389/fmed.2018.00109.
Crossref Google Scholar
[12]

G. Verna, M. Liso, E. Cavalcanti, et al., Quercetin administration suppresses the cytokine storm in myeloid and plasmacytoid dendritic cells, Int. J. Mol. Sci. 22 (2021) 8349. https://doi.org/10.3390/ijms22158349.
Crossref Google Scholar
[13]

V. Galleggiante, S. De Santis, E. Cavalcanti, et al., Dendritic cells modulate iron homeostasis and inflammatory abilities following quercetin exposure, Curr. Pharm. Des. 23 (2017) 2139-2146. https://doi.org/10.2174/1381612823666170112125355.
Crossref Google Scholar
[14]

M. Liso, A. Sila, G. Verna, et al., Nutritional regimes enriched with antioxidants as an efficient adjuvant for IBD patients under infliximab administration, a pilot study, Antioxidants 11 (2022) 138. https://doi.org/10.3390/antiox11010138.
Crossref Google Scholar
[15]

K. Petroni, M. Trinei, M. Fornari, et al., Dietary cyanidin 3-glucoside from purple corn ameliorates doxorubicin-induced cardiotoxicity in mice, Nutr. Metab. Cardiovasc. Dis. 27 (2017) 462-469. https://doi.org/10.1016/j.numecd.2017.02.002.
Crossref Google Scholar
[16]

B. Raspini, M. Vacca, D. Porri, et al., Early life microbiota colonization at six months of age: a transitional time point, Front. Cell. Infect. Microbiol. 11 (2021) 590202. https://doi.org/10.3389/fcimb.2021.590202.
Crossref Google Scholar
[17]

E. Bolyen, J.R. Rideout, M.R. Dillon, et al., Author correction: reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat. Biotechnol. 37 (2019) 1091. https://doi.org/10.1038/s41587-019-0252-6.
Crossref Google Scholar
[18]

E. Sommella, A. Carrizzo, F. Merciai, et al., Analysis of the metabolic switch induced by the spirulina peptide SP6 in high fat diet ApoE-/- mice model: a direct infusion FT-ICR-MS based approach, J. Pharm. Biomed. Anal. 195 (2021) 113865. https://doi.org/10.1016/j.jpba.2020.113865.
Crossref Google Scholar
[19]

M. Ciccarelli, F. Merciai, A. Carrizzo, et al., Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy), J. Pharm. Biomed. Anal. 217 (2022) 114827. https://doi.org/10.1016/j.jpba.2022.114827.
Crossref Google Scholar
[20]

R.D. Cohen, A.P. Yu, E.Q. Wu, et al., Systematic review: the costs of ulcerative colitis in Western countries, Aliment. Pharmacol. Ther. 31 (2010) 693-707. https://doi.org/10.1111/j.1365-2036.2010.04234.x.
Crossref Google Scholar
[21]

M.H. Holtmann, P.R. Galle, Current concept of pathophysiological understanding and natural course of ulcerative colitis, Langenbecks Arch. Surg. 389 (2004) 341-349. https://doi.org/10.1007/s00423-003-0448-5.
Crossref Google Scholar
[22]

M. Gajendran, P. Loganathan, A.P. Catinella, et al., A comprehensive review and update on Crohn’s disease, Dis. Mon. 64 (2018) 20-57. https://doi.org/10.1016/j.disamonth.2017.07.001.
Crossref Google Scholar
[23]

I. Khan, N. Ullah, L. Zha, et al., Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome, Pathogens 8 (2019) E126. https://doi.org/10.3390/pathogens8030126.
Crossref Google Scholar
[24]

I. Presti, G. D’Orazio, M. Labra, et al., Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect, Appl. Microbiol. Biotechnol. 99 (2015) 5613-5626. https://doi.org/10.1007/s00253-015-6482-8.
Crossref Google Scholar
[25]

M. Vacca, G. Celano, M.S. Lenucci, et al., In vitro selection of probiotics, prebiotics, and antioxidants to develop an innovative synbiotic (NatuREN G) and testing its effect in reducing uremic toxins in fecal batches from CKD patients, Microorganisms 9 (2021) 1316. https://doi.org/10.3390/microorganisms9061316.
Crossref Google Scholar
[26]

X. F. Zhang, X.X. Guan, Y.J. Tang, et al., Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis, Eur. J. Nutr. 60 (2021) 2855-2875. https://doi.org/10.1007/s00394-021-02503-5.
Crossref Google Scholar
[27]

A. Andoh, H. Kuzuoka, T. Tsujikawa, et al., Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease, J. Gastroenterol. 47 (2012) 1298-1307. https://doi.org/10.1007/s00535-012-0605-0.
Crossref Google Scholar
[28]

M. Kitabatake, Y. Matsumura, N. Ouji-Sageshima, et al., Persimmon-derived tannin ameliorates the pathogenesis of ulcerative colitis in a murine model through inhibition of the inflammatory response and alteration of microbiota, Sci. Rep. 11 (2021) 7286. https://doi.org/10.1038/s41598-021-86608-1.
Crossref Google Scholar
[29]

J.L. Benjamin, C.R.H. Hedin, A. Koutsoumpas, et al., Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota, Inflamm. Bowel Dis. 18 (2012) 1092-1100. https://doi.org/10.1002/ibd.21864.
Crossref Google Scholar
[30]

W. Wang, L. Chen, R. Zhou, et al., Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease, J. Clin. Microbiol. 52 (2014) 398-406. https://doi.org/10.1128/JCM.01500-13.
Crossref Google Scholar
[31]

Y.J. Goh, T.R. Klaenhammer, Genomic features of Lactobacillus species, Front. Biosci. (Landmark Ed). 14 (2009) 1362-1386. https://doi.org/10.2741/3313.
Crossref Google Scholar
[32]

T.T. Pizarro, L. Pastorelli, G. Bamias, et al., SAMP1/YitFc mouse strain: a spontaneous model of Crohn’s disease-like ileitis, Inflamm. Bowel Dis. 17 (2011) 2566-2584. https://doi.org/10.1002/ibd.21638.
Crossref Google Scholar
[33]

Y. Mei, H. Chen, B. Yang, et al., Research progress on conjugated linoleic acid bio-conversion in Bifidobacterium, Int. J. Food Microbiol. 369 (2022) 109593. https://doi.org/10.1016/j.ijfoodmicro.2022.109593.
Crossref Google Scholar
[34]

H.U. Celebioglu, Effects of potential synbiotic interaction between Lactobacillus rhamnosus GG and salicylic acid on human colon and prostate cancer cells, Arch Microbiol. 203 (2021) 1221-1229. https://doi.org/10.1007/s00203-021-02200-1.
Crossref Google Scholar
[35]

P. Wang, D. Li, W. Ke, et al., Resveratrol-induced gut microbiota reduces obesity in high-fat diet-fed mice, Int. J. Obes. (Lond). 44 (2020) 213-225. https://doi.org/10.1038/s41366-019-0332-1.
Crossref Google Scholar
[36]

X. Si, J. Bi, Q. Chen, et al., Effect of blueberry anthocyanin-rich extracts on peripheral and hippocampal antioxidant defensiveness: the analysis of the serum fatty acid species and gut microbiota profile, J. Agric. Food Chem. 69 (2021) 3658-3666. https://doi.org/10.1021/acs.jafc.0c07637.
Crossref Google Scholar
[37]

H. Ma, A. Hou, J. Tang, et al., Antioxidant activity of vitis davidii foex seed and its effects on gut microbiota during colonic fermentation after in vitro simulated digestion, Foods 11 (2022) 2615. https://doi.org/10.3390/foods11172615.
Crossref Google Scholar
[38]

J. Zhang, G. Yang, Y. Wen, et al., Intestinal microbiota are involved in the immunomodulatory activities of longan polysaccharide, Mol. Nutr. Food Res. 61 (2017). https://doi.org/10.1002/mnfr.201700466.
Crossref Google Scholar
[39]

A. Quagliariello, F. Del Chierico, S. Reddel, et al., Fecal microbiota transplant in two ulcerative colitis pediatric cases: gut microbiota and clinical course correlations, Microorganisms 8 (2020) E1486. https://doi.org/10.3390/microorganisms8101486.
Crossref Google Scholar
[40]

M. Schirmer, E.A. Franzosa, J. Lloyd-Price, et al., Dynamics of metatranscription in the inflammatory bowel disease gut microbiome, Nat. Microbiol. 3 (2018) 337-346. https://doi.org/10.1038/s41564-017-0089-z.
Crossref Google Scholar
[41]

J. Feurle, E. Espinosa, S. Eckstein, et al., Escherichia coli produces phosphoantigens activating human gamma delta T cells, J. Biol. Chem. 277 (2002) 148-154. https://doi.org/10.1074/jbc.M106443200.
Crossref Google Scholar
[42]

S. Huang, D. Pang, X. Li, et al., A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice, Food Funct. 10 (2019) 3224–3236. https://doi.org/10.1039/c9fo00263d.
Crossref Google Scholar
[43]

R. Tan, M. Jin, Z. Chen, et al., Exogenous antibiotic resistance gene contributes to intestinal inflammation by modulating the gut microbiome and inflammatory cytokine responses in mouse, Gut Microbes. 15 (2002) 2156764. https://doi.org/10.1080/19490976.2022.2156764.
Crossref Google Scholar
[44]

G.W. Sewell, Y.A. Hannun, X. Han, et al., Lipidomic profiling in Crohn’s disease: abnormalities in phosphatidylinositols, with preservation of ceramide, phosphatidylcholine and phosphatidylserine composition, Int. J. Biochem. Cell Biol. 44 (2012) 1839-1846. https://doi.org/10.1016/j.biocel.2012.06.016.
Crossref Google Scholar
[45]

C. Tefas, C. Socaciu, C. Moraru, et al., Lipidomic signatures of colonic inflammatory bowel diseases: a pilot study, J. Gastrointestin. Liver. Dis. 28 (2019) 246-247. https://doi.org/10.15403/jgld-188.
Crossref Google Scholar
[46]

D. Horta, M. Moreno-Torres, M.J. Ramírez-Lázaro, et al., Analysis of the association between fatigue and the plasma lipidomic profile of inflammatory bowel disease patients, J. Proteome Res. 20 (2021) 381-392. https://doi.org/10.1021/acs.jproteome.0c00462.
Crossref Google Scholar
[47]

Q. Yang, Z. Huang, H. Liu, et al., Uhplc-MS/MS-based plasma lipidomics reveal alterations associated with exclusive enteral nutrition treatment in adult patients with active Crohn’s disease, Inflamm. Bowel Dis. 28 (2022) S77-S78. https://doi.org/10.1093/ibd/izac015.126.
Crossref Google Scholar
[48]

F. Fan, P.A. Mundra, L. Fang, et al., Lipidomic profiling in inflammatory bowel disease: comparison between ulcerative colitis and crohn’s disease, Inflamm. Bowel Dis. 21 (2015) 1511-1518. https://doi.org/10.1097/MIB.0000000000000394.

Crossref Google Scholar
Food Science and Human Wellness
Volume 13 Issue 6,
November 2024
Pages 3536-3543
DOI: 10.26599/FSHW.2023.9250036
Cite this article:
Vacca M, Sommella EM, Liso M, et al. Anthocyanins from purple corn affect gut microbiota and metabolome in inflammatory bowel disease patients under infliximab infusion: the SiCURA pilot study. Food Science and Human Wellness, 2024, 13(6): 3536-3543. https://doi.org/10.26599/FSHW.2023.9250036

755

Views

101

Downloads

1

Crossref

1

Web of Science

1

Scopus

0

CSCD

Altmetrics
Received: 31 January 2023
Revised: 30 March 2023
Accepted: 17 April 2023
Published: 18 December 2024
© 2024 Beijing Academy of Food Sciences. Publishing services by Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return